Prognostic value of proangiogenic cytokines in children with lymphomas

Pediatric Blood and Cancer

Volumn 53, Issue 7, 2009, Pages 1195-1199

  Mizia Malarz, Agnieszka ^a   Sobol, Grazyna ^a   Janowska, Joanna ^a   Wos, Halina ^a   Zahorska Markiewicz, Barbara ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Angiogenesis; Cytokines; Lymphoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VASCULOTROPIN; VINBLASTINE; VINCRISTINE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 2; TUMOR PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TREATMENT FAILURE; FEMALE; HODGKIN DISEASE; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; LYMPHOMA; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); PATHOPHYSIOLOGY; REMISSION; SURVIVAL; TREATMENT FAILURE;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DISEASE PROGRESSION; FEMALE; FIBROBLAST GROWTH FACTOR 2; HODGKIN DISEASE; HUMANS; LYMPHOMA; LYMPHOMA, NON-HODGKIN; MALE; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449721067     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22179     Document Type: Article

References (27)

1. Kowalczyk JR, Dudkiewicz E, Balwierz W, et al. Incidence of childhood cancers in Poland in 1995-1999. Med Sci Monit 2002;8:587-590.
2. Bogusławska-Jaworska J. Nieziarnicze chłoniaki złośliwe u dzieci. In: Krzakowski M, editor. Onkologia kliniczna. Wrocław: Wyd Med Borgis; 2001. pp. 657-671.
3. Bogusławska-Jaworska J. Choroba Hodgkina u dzieci. In: Krzakowski M, editor. Onkologia kliniczna. Wrocław: Wyd Med Borgis; 2001. pp. 644-656.
4. Bellamy WT, Richter L, Frutiger Y, et al. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999;59:728-733.
5. Kadowaki I, Ichinohasama R, Herigae H, et al. Accelerated lymphangiogenesis in malignant lymphoma: Possible role of VEGF-A and VEGF-C. Br J Hematol 2005;130:869-877.
6. Karpanen T, Egebla M, Karkkainen MJ, et al. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2005;61:1786-1790.
7. Poon RTP, Fan TS, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-1225.
8. Pedersen LM, Klausen TW, Davidsen UH, et al. Early changes in serum Il-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma. Ann Hematol 2005;84:510-516.
9. Bertolini F, Paolucci M, Peccatori F, et al. Angiogenic growth factors and endostatin in non-Hodgkin's lymphoma. Br J Hematol 1999;106:504-509.
10. Kerbel RS. Tumor angiogenesis: Past, present and the near future. Carcinogenesis 2000;21:401-410.
11. Dina A, Zahava V, Iness M. The role of vascular endothelial growth factor in Langerhans cell histiocytosis. Hematol Oncol 2005;27:62-66.
12. Villela L, Lopez-Guillermo A, Montono S, et al. Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer 2001;91:1557-1562.
13. Ferrara N. Role of VEGF in the regulation of angiogenesis. Kidney Int 1999;56:794-814.
14. Salven P, Orpana A, Teerenhovi L, et al. Simultaneos elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: A single institution study of 200 patients. Blood 2000;96:3712-3718.
15. Salven P, Teerenhovi L, Joensuu H. A high pretreatment serum vascular endothelial growth factor concentration is associated with poor outcome in non-Hodgkin's lymphoma. Blood 1997;90:3167-3172.
16. Ho CL, Sheu LF, Li CY. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 2003;7:1-8.
17. Koster A, Raemaekers JM. Angiogenesis in malignant lymphoma. Curr Opin Oncol 2005;17:611-616.
18. Smolej L, Andrys C, Maisnar V, et al. Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica 2005;48:57-58.
19. Salgado R, Benoy I, Bogers J, et al. Platelets and vascular endothelial growth factor (VEGF):Amorphological and functional study. Angiogenesis 2001;4:37-43.
20. Karkkainen MJ, Petrova TU. VEGF receptors in the regulation of angiogenesis. Oncogene 2000;19:5598-5601.
21. Plavcovic H, Schutz VV, Rossler J, et al. Quantification of angiogenesis stimulators in children with solid malignancies. Int J Cancer 2001;92:756-760.
22. Davidoff AM, Kandel JJ. Antiangiogenic therapy for the treatment of pediatric solid malignancies. Semin Pediatr Surg 2004;13:53-60.
23. Tabone MD, Landman-Parker J, Arcil B, et al. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors? Clin Cancer Res 2001;7:538-543.
24. Ben Arush MW, Schenzer P, Maurice S, et al. Serum vascular endothelial growth factor as a significant marker of treatment response in pediatric malignancies. Pediatr Hematol Oncol 2005; 22:513-524.
25. El Houseini ME, Abdel Azim SAF, El Desouky GI, et al. Clinical significance of vascular endothelial growth factor (VEGF) in sera of patients with pediatric malignancies. J Egypt Nat Cancer Inst 2004;16:57-61.
26. Rowe DH, Huang J, Kayton ML. Anti-VEGF antibody suppresses primary tumor growth and metastasis in an experimental model of Wilms' tumor. J Pediatr Surg 2000;35:30-34.
27. Yetgkin S, Yenicesu I, Cetin M, et al. Clinical importance of serum vascular endothelial and basic fibroblast growth factors in children with acute lymphoblastic leukemia. Leuk Lymph 2001;42:83-88.